Paul helps drive partnering, business development, and strategic transactions for RTW and its portfolio companies, including JiXing Pharmaceuticals and Yarrow Biotechnology.
Prior to joining RTW, Paul was Global Head of Business Development & Alliances at Hansoh Pharma, responsible for expanding its innovative pipeline through partnerships, where he built and led Hansoh's U.S. discovery research site. Before Hansoh, he led Global Business Development at Hengrui Medicine, overseeing licensing, M&A, and strategic investments. Earlier in his career he advised pharmaceutical, biotech, and healthcare services companies as a member of Lazard’s healthcare investment banking group, executing complex M&A, cross-border, and restructuring transactions.
In a way, discovering and developing new medicines is hacking the code of biology – it can be incredibly challenging, like running an uphill marathon full of roadblocks. Yet, we must not stop innovating and persevering for people in need. At RTW, we are committed to be the best long-term partner in this journey. We are in this race together, and we will bring life-changing medicines to patients and caregivers around the world.
Paul was a co-founder and President of The Biotechnology and Life Sciences Advising (BALSA) Group, a nonprofit consulting organization based in St. Louis.
Paul received an MBA from Harvard Business School, where he was a Robert S. Kaplan Life Sciences Fellow, a PhD in Neuroscience from Washington University in St. Louis, and a bachelor’s degree in Biological Sciences and Chemistry from University of Waikato in New Zealand.